OBJECTIVE: To investigate the effects of leptin administration to Psammomys obesus, a polygenic animal model of obesity and type 2 diabetes mellitus. DESIGN: Longitudinal intervention study utilising three separate leptin treatment protocols lasting 7 ± 14 d. MEASUREMENTS: Body weight and food intake were measured daily, body fat and muscle content were estimated by carcass analysis on completion of the study. Blood glucose, plasma insulin, leptin, triglycerides and cholesterol were measured at baseline and twice each week during the study. RESULTS: Relatively high doses of leptin were required to signi®cantly reduce food intake and body fat content in lean Psammomys obesus, but had no discernible effect on their obese littermates. CONCLUSION: As a species, Psammomys obesus appear to be relatively insensitive to the effects of leptin administration, compared with other rodents. Obese Psammomys obesus are leptin resistant relative to their lean littermates.
Introduction
Leptin is a cytokine-like hormone secreted from adipose tissue and is thought to act on the hypothalamus to reduce food intake and increase energy expenditure. 1 It has been proposed that leptin may represent a therapeutic agent for human obesity.
The administration of daily intraperitoneal (i.p.) injections of exogenous leptin (5 mgakg body weight) to obaob mice, which have no circulating endogenous leptin, resulted in rapid and signi®cant reductions in body weight and food intake.
2 ± 4 A smaller but still signi®cant decrease in body weight was noted in wild-type mice treated with the same leptin dose. 3 When wild-type mice were treated with 25 mg leptinakgad signi®cant reductions in body weight, food intake and body fat content were observed. 3 In dbadb mice, which have a defective hypothalamic leptin receptor 5 and elevated circulating leptin levels, daily leptin administration of 5± 10 mgakg had no detectable effect on food intake or body weight. 2, 3 Intracerebroventricular (ICV) administration of leptin to faafa rats showed that very high doses of leptin (10 times that required in wild-type animals) were required to reduce food intake in these animals. 6 Faafa rats, like dbadb mice have a genetic mutation in the leptin receptor. Camp®eld et al 2 administered leptin to diet-induced obese (DIO) mice and found that the dose required for a signi®cant decrease in body weight and food intake was ®ve times that which produced similar results in the obaob mouse.
Administration of leptin (5 mgakgad) to obaob mice also normalised their hyperglycaemia and hyperinsulinaemia to the levels of lean, control mice within several days. 4 No signi®cant effects on blood glucose or plasma insulin concentrations were detected in wild-type mice treated with leptin. 4 The data regarding the effects of peripheral leptin administration in polygenic animal models of obesity, with relatively high circulating leptin levels, which would therefore more closely resemble the obesity observed in human populations, are quite limited. One study found that DIO mice of the strain AKRaJ, but not New Zealand Obese (NZO) or yellow Agouti (A y ) mice, responded to peripheral leptin administration at relatively high dosage (25 mgakgad). 7 In the current study we investigated the effects of leptin administration in Psammomys obesus (Israeli Sand rat), a unique animal model of obesity and non-insulin-dependent diabetes mellitus (NIDDM). Psammomys obesus exhibit a complete spectrum of body weight and blood glucose and plasma insulin concentrations, when fed an ad libitum diet of normal laboratory chow. 8, 9 This heterogeneous response makes Psammomys obesus more analogous to the pattern of human obesity and NIDDM than the homogeneous single-gene models of obesity such as the obaob and dbadb mice. 10 We have previously shown that the ob gene is expressed exclusively in adipose tissues of Psammomys obesus, and that the obese animals have hyperleptinaemia compared to their lean littermates. 11, 12 In addition, we have found an apparent dysregulation of leptin in the response to fasting in obese, insulinresistant Psammomys obesus. 13 Obese, insulinresistant Psammomys obesus, fasted for 24 h, failed to exhibit the predicted reduction in plasma leptin concentrations observed in lean Psammomys obesus, as well as other rodents and humans, 13 suggesting a role for leptin in the disease process in obese Psammomys obesus.
The aim of this study was to determine the effects of leptin administration in Psammomys obesus with a range of body weight and blood glucose and plasma insulin concentrations.
Methods

Animals
A Psammomys obesus colony is maintained at Deakin University (Geelong, Australia), with the breeding pairs fed a diet of lucerne and chow, ad libitum. Experimental animals were weaned at four weeks of age and given a diet of standard laboratory chow, from which 12% of energy was derived from fat, 63% from carbohydrate and 25% from protein (Barastoc, Pakenham, Australia). Animals were housed in a temperature controlled room (22 AE 1 C) with a 12 h light:12 h dark cycle. The animals used in the study were aged 16±20 weeks during the pretreatment period.
Psammomys obesus were categorised into groups as previously described. 6, 9 Obese animals weighed b 190 g at 12 weeks of age. Previous studies have shown that these animals had signi®cantly greater body fat content than those classi®ed as lean (body weight`190 g at 12 weeks of age). 11, 12, 14 Experimental protocol A group of Psammomys obesus were housed individually and followed for at least a 7 d period, with free access to food and water, to establish baseline data for food intake (measured by the rate of disappearance), body weight, blood glucose and plasma insulin concentrations. The animals were characterised (as described above) into lean or obese groups (n 24 in each group). Within each of these groups, animals were paired into two treatment groups (leptin-treated and control) matched for body weight, gender, age, blood glucose and plasma insulin concentrations. Lean and obese animals were paired according to age, gender, body weight, blood glucose and plasma insulin concentrations into two groups (n 10), leptintreated and controls. Throughout the 14 d study period, the animals were given a single daily i.p. injection of 5 mg leptinakg body weight (kindly supplied by Dr Margery Nicolson, Amgen Inc., CA) or 5 ml phosphate-buffered salineakg body weight (equivalent volume to leptin injection) at 10.00 h. Body weight was measured daily and blood was collected into heparinised tubes in the fed state twice weekly at 09.00 h.
Continuous infusion (0.8 mgakgad)
To study the effects of continuous infusion of leptin in Psammomys obesus, animals were surgically implanted with osmotic minipumps (Alzet model 2002, Alza, CA). The pumps delivered a constant dose of 0.5 mlah for 14 d. The pumps implanted in leptin-treated animals (n 6 in each of lean and obese groups) contained leptin with the concentration adjusted so that the animals received a dose of 0.8 mg leptin per kg body weight per day. Control animals (n 6 in group) received an equivalent volume (0.5 mlah) of saline for 14 d. During the two weeks of the study period, body weight and food intake were measured, and blood collected at 11.00 h in the fed state for biochemical analyses on day 4, day 7, day 11 and day 14.
Daily injections (45 mgakgad i.p.)
The effects of treatment with very large doses of leptin were investigated in a`supraphysiological study'. After the baseline period, animals were given i.p. injections three times per day (at 08.00 h, 16.00 h and 24.00 h) with 15 mg leptin per kg body weight (n 8 lean, n 8 obese), or equivalent volume of saline for control animals (n 8 lean, n 8 obese), for a total of seven days. This dosage of leptin resulted in a total of 45 mgakgad. Body weight and food intake were measured daily throughout the study. In addition, blood was collected from the animals on day 2, day 4 and day 7 at midday (the midpoint between the morning and afternoon injections) for biochemical analyses. Each day the pair-fed animals were given the same amount of chow as that consumed by age-, gender-and body weight-matched animals receiving leptin.
At the completion of each of the studies, the animals were killed by anaesthetic overdose (120 mgakg pentobarbitone) and selected fat depots (interscapular, perirenal, epididymal, mesenteric and intramuscular) were removed and weighed to allow an estimate of body fat content. The weights of the various fat depots were combined and divided by total body mass to provide this estimate. In addition, several major muscles (soleus, gastrocnemius, plantaris and extensor digitalis longus) were removed and weighed to provide an estimate of leg muscle mass, a crude indicator of the animal's lean body mass.
Leptin treatment in Psammomys obesus K Walder et al All of the experiments described above were carried out following the Australian National Health and Medical Research Council (NHMRC) principles of laboratory animal care and approved by the Deakin University Animal Ethics Committee.
Analytic methods
Whole blood glucose was measured using an enzymatic glucose analyser (Model 27, Yellow Springs Instruments, OH). Plasma insulin concentrations were determined using a double antibody solid phase radioimmunoassay (Phadeseph, Kabi Pharmacia Diagnostics, Sweden). Plasma leptin levels were measured in collaboration with Amgen Inc. (Thousand Oaks, CA) using a solid phase double enzyme immunoassay (EIA) with af®nity puri®ed polyvalent antibodies. Leptin concentrations in the plasma samples were calculated from standard curves generated with recombinant murine leptin. The limits of detection for the leptin EIA were 20 pgaml of serum or plasma. The inter-assay CV was 7.7% for the high standard and 10.5% for the low standard. Plasma triglyceride and cholesterol concentrations were measured using colorimetric kits (Boehringer Mannheim, Mannheim, Germany) on an automatic analyser (Hitachi 705-0013, Tokyo, Japan).
Ob gene expression was measured by semi-quantitative reverse transcription polymerase chain reaction as the expression of ob, relative to b-actin, using a previously described method. 12 
Statistical analysis
All experimental data are expressed as meansAE s.e.m. A one-way analysis of variance in combination with a Tukey's multiple comparison test was used to compare means between and within groups, and a two-sampled unpaired t-test was used where appropriate. In all instances probability values of`0.05 were considered signi®cant.
Results
Body weight
Both continuous infusion (0.8 mgakgad) and single daily i.p. injections (5 mgakgad) of leptin, had no effect on body weight in either lean or obese Psammomys obesus (Figure 1 ). Within the lean and obese groups of animals, there was no signi®cant difference between the leptin-treated and control groups, either before or after the treatment, and none of the groups had a signi®cant change in body weight during the study. In lean animals treated with 45 mgakg leptin per day, there was a signi®cant difference in maximum percentage body weight change compared with control animals (Figure 1 ). Lean Psammomys obesus, pairfed to the amount consumed by the leptin-treated animals, exhibited a similar reduction in body weight, suggesting that this change resulted primarily as a result of decreased energy intake rather than altered energy expenditure. In obese animals, treated with 45 mgakg leptin per day, no signi®cant difference in body weight was observed compared with controls.
The body fat content of the animals, estimated by weighing several major fat depots relative to total body weight, was unaffected by continuous infusion (0.8 mgakgad) and single daily i.p. injections (5 mgakgad) of leptin ( Figure 2 ). However, administration of 45 mg leptinakg body weightad signi®cantly reduced the estimated body fat content in lean (P 0.031), but not obese, animals ( Figure 2 ). Estimated body fat content was signi®cantly higher in obese control animals relative to lean controls (P 0.004), con®rming the de®nition of these animals as`obese'.
Leg muscle mass, as estimated by the weight of selected muscle groups, was also unaffected by any of the forms of leptin treatment, detailed above, in both obese and lean animals relative to controls. In addition, there was no difference in the estimated leg muscle mass between lean and obese Psammomys obesus (1.6 AE 0.2% vs 1.7 AE 0.2%). This con®rmed our previous ®ndings in these animals, 11 and supported the contention that Psammomys obesus Figure 1 Maximum body mass change in lean and obese Psammomys obesus in response to leptin as a percentage of initial mass (mean AE s.e.m.; *P`0.05). 
Food intake
Treatment of lean Psammomys obesus with 5 mgakgad leptin by single daily i.p. injection or 0.8 mgakgad by continuous infusion, had no signi®-cant effect on the food intake of the animals. High dose leptin treatment (45 mgakgad) signi®cantly reduced food intake in lean animals compared with their baseline consumption (9.67AE 0.87 gad vs 12.4AE 0.66 gad; P 0.03; Figure 3 ). All forms of leptin treatment tested had no signi®cant effect on food intake in obese animals ( Figure 3 ).
Blood glucose and plasma insulin
Blood glucose and plasma insulin concentrations were not signi®cantly affected by any of the forms of leptin administration utilised in this study in either lean or obese Psammomys obesus (Table 1) .
Plasma leptin
Obese Psammomys obesus had signi®cantly higher circulating plasma leptin concentrations at baseline, compared with their lean littermates (P`0.05). As we have shown previously, leptin concentrations were positively correlated with body weight in these animals, similar to what has been shown in human populations. 15, 16 No change was found in either (lean or obese) group after treatment with 5 mg leptinakgad by i.p. injection, when measured throughout the study in blood collected just before the daily injections (Table 1) . Similarly, continuous infusion of leptin (0.8 mgakgad) for 14 d resulted in no signi®cant changes in circulating plasma leptin concentrations in either group of Psammomys obesus (Table 1) .
After i.p. injection of 15 mg leptinakg body weight, no signi®cant differences were observed in the maximal circulating leptin levels detected in lean animals Figure 4 is for a combination of lean and obese Psammomys obesus. Figure 4 shows the effects of an individual injection of 15 mg leptinakg body weight on plasma leptin concentrations for the period until the next dose. One hour after injection, mean plasma leptin concentrations were increased by a factor of 314. Three hours later, at the midpoint between injections, plasma leptin was 84 times baseline levels, and 7 h after the injection, just prior to the next dose, plasma leptin concentrations were still signi®cantly increased (four times) compared with baseline levels.
As shown in Table 1 , plasma leptin concentrations at midday (midpoint between injection times) were signi®cantly increased in the leptin-treated animals (45 mgakgad) throughout the study (approximately 80 times baseline levels on day 4 and day 7).
Triglycerides and cholesterol
Administration of 45 mg leptinakg body weightad had no signi®cant effects on plasma triglyceride or total cholesterol concentrations in either lean or obese Psammomys obesus (Table 2) . 
Discussion
In this study we have shown that Psammomys obesus, as a species, appear to be less sensitive to the anorexigenic effects of exogenous leptin administration relative to other rodents. In addition, obese Psammomys obesus exhibited greater resistance to the effects of leptin on body fat content, body weight and food intake compared with their lean littermates.
We have previously shown that ob gene expression and circulating endogenous leptin concentrations are elevated in obese Psammomys obesus relative to their lean littermates. 11, 12 Plasma leptin concentrations in Psammomys obesus were found to correlate signi®-cantly with body weight, body fat content and plasma insulin concentrations, 12 similar to what has been observed in human populations. 15, 16 Therefore, studies of leptin treatment in Psammomys obesus may represent what is likely to happen in leptin administration to humans more closely than studies in animal models such as the obaob mouse, which has no circulating leptin. 1 Leptin administration of 5 mgakg body weight for 14 d had no signi®cant effect on food intake, body weight, percentage body fat, blood glucose or plasma insulin concentration in lean or obese Psammomys obesus. This dosage was suf®cient to signi®cantly reduce all of these parameters in obaob mice, 2 ± 4 and in general it appeared that a daily dose of 5± 10 mg leptinakg body weight, approximately halved food intake and caused a 10±40% reduction in body weight within 2±4 weeks in these animals.
3,4 A smaller but still signi®cant decrease in body weight was noted in wild-type mice treated with the same leptin dose. 3 In a previous study, continuous infusion of leptin at a dosage of 0.3 mgakgad in wild-type mice for 14 d caused a signi®cant reduction in body weight, which was partly attributed to a decrease in food intake. 4 We used the same methodology in a range of Psammomys obesus, but increased the dose to 0.8 mgakgad. No signi®cant changes were observed in food intake, body weight, percentage body fat, blood glucose or plasma insulin concentrations in lean or obese Psammomys obesus, continuously infused with 0.8 mg leptinakgad for 14 d. These results con®rmed the relative leptin resistance of this species, compared with other rodents, and suggested that very high doses Plasma leptin concentrations in Psammomys obesus after an injection of 15 mg leptin per kg body weight or an equivalent volume of saline (control animals; mean AE s.e.m.; *P`0.05). of leptin may be required to elicit signi®cant effects on food intake and body fat content in Psammomys obesus. To achieve very high circulating concentrations of leptin in Psammomys obesus, both lean and obese animals were treated with 45 mg leptinakgad (injections of 15 mgakg every eight hours) for seven days. The plasma leptin concentrations achieved after a single injection in this study are shown in Figure 4 . One hour after injection, in the leptin-treated group, the plasma leptin levels rose to b 300 times baseline levels, and three hours later they were still approximately 80 times baseline concentrations. The plasma leptin concentrations remained signi®cantly elevated (four times baseline) just prior to the next injection, indicating that throughout this study, plasma leptin was maintained at signi®cantly increased (`supraphysiological') concentrations compared with baseline levels. By calculating the area under the curve (AUC) shown in Figure 4 , the mean plasma leptin concentrations in these animals for the duration of the study was estimated to be 3062 ngaml or 125 times baseline levels.
In lean Psammomys obesus, this method of leptin treatment reduced food intake (Figure 3) , percentage body fat ( Figure 2 ) and resulted in signi®cantly different maximum percentage body weight change throughout the study compared with control animals (Figure 1 ). These ®ndings showed that the murine leptin used in all of these studies was effective in Psammomys obesus, but that very high doses were required compared with those used in obaob and wildtype mice.
In obese Psammomys obesus, treatment with very large doses of leptin had no signi®cant effect on food intake, body weight or body fat content, indicating that these animals were signi®cantly leptin resistant, relative to their lean littermates. Therefore insensitivity to the anorexigenic actions of leptin was implicated in the pathophysiology of obesity and insulin resistance to these animals. Because the animals were housed identically, it appears that some genetic predisposition found in obese Psammomys obesus renders these animals relatively insensitive to the actions of their endogenous leptin, compared with lean Psammomys obesus. This defect could represent an expression of the thrifty genotype. That is, these animals could accumulate body fat more readily when food is available, unhindered by the anorexigenic effects of their circulating leptin. Conversely, the animals lacking this genotype would limit body fat accumulation, when food is plentiful, due to increases in circulating leptin which would result in decreased food intake and increased energy expenditure.
Previous studies have shown that an increased dose of exogenous leptin (administered peripherally) is required to have an effect on food intake and body fat in DIO mice. 7, 17 NZO and A y mice appear to be totally unresponsive to peripheral leptin administration. 7 Studies utilising the technique of ICV cannulation, have shown that both DIO and NZO mice responded normally to centrally administered leptin, but A y mice had greatly reduced responsiveness to ICV leptin. 7 It was therefore concluded that the obesity of NZO mice (and possibly DIO mice), was due to reduced transport of leptin across the blood-brain barrier (BBB), while the likely defect in A y mice was in the neural pathway (including the melanocortin-4 receptor) activated by leptin. 7 In view of these studies, one could postulate that the defect in obese Psammomys obesus could also reside in one of these areas. We have investigated the leptin receptor in both lean and obese Psammomys obesus and found no difference in sequence, suggesting that a primary defect in the leptin receptor gene is unlikely to be responsible for the obesity in these animals. 11 However, a transport defect into the cerebrospinal¯uid (as in NZO mice) or a defect downstream of the leptin receptor in obese but not lean Psammomys obesus, cannot be excluded at this time.
Previous studies in Psammomys obesus have shown it to be a polygenic, heterogeneous model of obesity and NIDDM displaying a continuous range of metabolic responses to a normal chow diet. In a laboratory setting, on a diet of normal laboratory chow, a signi®cant proportion of these animals develop hyperinsulinaemia, hypertriglyceridaemia, hypercholesterolaemia and elevated leptin levels, making it a unique model of obesity and NIDDM. 11, 12, 14 The phenotypic range of body weight and plasma leptin concentrations in Psammomys obesus make it more analogous to human obesity than the single-gene mutant models such as obaob mice. Therefore the ®ndings of these studies may be particularly relevant to the use of leptin as a therapeutic agent for human obesity. It appears that Psammomys obesus may exhibit a range of sensitivity to exogenous leptin administration, which may be inversely related to the circulating leptin concentrations. Therefore, the more obese the animal, the higher levels of circulating leptin may be required to signi®cantly affect food intake and body fat content. If very high circulating levels of leptin are required to reduce food intake and body fat in human obesity, then potential side effects of this pharmacological hyperleptinaemia, including possible direct effects on the pancreas, 18 liver 19 and adipose tissue 20 will need to be extensively investigated.
